New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...

High-dose docosahexaenoic acid (DHA) supplementation does not yield a change in brain volume or cognitive performance over 24 months, according to a study publi ...

Those using upadacitinib had lower risk for discontinuing treatment, regardless of previous exposure to treatment ...

Rituximab noninferior to ocrelizumab for suppressing disease activity on T2-weighted MRI between 6 and 24 months.

For most people, the risk for serious muscle disorders from statins is low, according to a study published online June 25 in The Lancet. Ting Cai, DPhil, from t ...

Casgevy is the first gene therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 2 and older.

When a hospital mistakenly destroyed a patient's placenta despite a signed release form, it faced a lawsuit — and a lesson in what truly constitutes "waste." ...

The 12-month wind-down for therapeutics and 180-day transition for medical devices signal a definitive shift back to standard regulatory pathways, forcing manufacturers like Invivyd to pursue full FDA ...

The products may now carry a claim telling smokers that switching to ZYN "puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis." ...

The FDA released a list of participants for a 2-day July meeting of its Pharmacy Compounding Advisory Committee; at least 7 members have ties to peptide businesses.

HbA1c level change from baseline was at least as large with bofanglutide as with semaglutide. HealthDay News — For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 ...

It is increasingly recognized that galactose-deficient IgA in the glomerulus activates the alternative complement system and drives IgA nephropathy, including in the tubules and interstitium, leading ...